CClinicalTrials.gg
RecruitingNCT07568093Updated May 5, 2026

PARO-agitation-study

An interventional study of PARO in Agitation, POSTOPERATIVE DELIRIUM AND POSTOPERATIVE COGNITIVE DECLINE and Anxiety After Surgery, sponsored by Hannover Medical School. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Hannover Medical School · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2025, registered Apr 2026).
  • Started Dec 2025; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Postoperative agitation is a common and serious complication in visceral and transplant surgery, associated with prolonged hospital stays and an increased risk of self-harm. Therefore, it is important to find an approach to improve the management of postoperative agitation and to reduce its duration and severity. The medical device "PARO" is a robotic seal that enables patient-robot-interaction. Patients respond to the device through verbal communication and motor responses, as well as facial expressions and gestures. The seal detects human interaction through audiovisual recognition, tactile sensors, and the integration of artificial intelligence. The aim of the study is to observe the use of "PARO" in patients undergoing elective visceral surgery and to analyze the occurence of agitation.

A decrease in the incidence of postoperative agitation is to be expected in a cohort of patients undergoing visceral surgery who use PARO compared to a group of patients undergoing visceral surgery who do not use PARO.

To monitor the occurrence of postoperative agitation, a standardized screening will be conducted twice daily for three days using the Richmond Agitation-Sedation Scale (RASS). To assess postoperative pain, anxiety and delirium, the Numerical Pain Scale (NRS), the State-Trait-Anxiety-Inventory (STAI) and a delirium screening tool (3D-CAM/CAM-ICU) are used by a trained study team. The occurrence of other neuropsychiatric symptoms and postoperative surgical complications will also be assessed.

Additionally, the interaction between PARO and the patients is analyzed regarding movements, reactions to haptic and auditory stimuli, and the frequency of interaction. Our approach involves quantitatively monitoring these metrics to collect sensor data from the robot and video recordings of the patients to identify facial expression and posture patterns. The use and acceptance of the robot on clinical wards by various professional groups are evaluated. The focus is particularly on nursing staff, who have the most interactions with patients. The project is complemented by a hygiene study examining how successfully the hygiene protocol is integrated into clinical routines and what challenges the use of PARO poses in an intensive care unit. The aim is also to examine the workflow and time-related aspects of its usage. The study will be submitted as a clinical trial of the medical device within its intended use, without any additional invasive or burdensome procedures, in accordance with the provisions of Section 15 of the Medical Practitioners Act (MBO).

02

Conditions studied

  • Agitation
  • POSTOPERATIVE DELIRIUM AND POSTOPERATIVE COGNITIVE DECLINE
  • Anxiety After Surgery
  • Postoperative Pain

Keywords

  • Agitation, postoperative Delirium, Anxiety
03

In context

Psychomotor Agitation

500 studies on the registry are indexed under Psychomotor Agitation; 55 are open to participants now.

This study's planned enrollment of 300 is above the median of 90 across 413 interventional studies indexed under Psychomotor Agitation.

Browse Psychomotor Agitation studies →

Lead sponsor

Hannover Medical School is the lead sponsor of 198 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patient inclusion criteria:

  • ≥18 years of age
  • Elective visceral surgery
  • german-speaking
  • Patient is capable of giving informed consent

Patient exclusion criteria:

  • Known dementia
  • Known immunodeficiency
  • Anacusia
  • Acute damage to the central nervous system
  • A preoperative systemic infection
  • Pre-existing severe immunosuppression or colonization with multidrug-resistant organisms (methicillin resistant Staphylococcus aureus (MRSA), quadruple multidrug-resistant Gram-negative pathogens (MRGN), Candida auris, vancomycin-resistant enterococci (VRE), and linezolid-resistant enterococci (LRE))
  • Postoperative systemic infection
  • Drug dependence
  • Known chronic pain syndrome
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • No intervention
    Standard of care
  • Other
    Standard of care + PARO

    Device: PARO

Interventions

  • DevicePARO

    Robotic Seal "PARO"

06

What researchers measure

Primary outcomes

  1. Agitation

    measured via Richmond-agitation-sedation-scale (RASS)

    Time frame: 1.-3.postoperative days

Secondary outcomes

  1. Postoperative anxiety

    measured via State-Trait-Anxiety-Inventory (STAI)

    Time frame: Postoperative days 1-3

  2. Postoperative pain

    measured via Numeric-Rating-scale (NRS)

    Time frame: Postoperative days 1-3

  3. Postoperative delirium

    measured via 3D-CAM/CAM-ICU

    Time frame: Postoperative days 1-3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The data that support the findings of this study are available, but restrictions apply to the availability of these data, which were used under licence for the current study and so are not publicly available. The data are, however, available from the authors.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07568093
Lead sponsor
Hannover Medical School
Responsible party
Worthmann, Hans MD, MHBA (PD Dr., Hannover Medical School) — Principal investigator
First posted
May 5, 2026
Start date
Dec 15, 2025
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
May 5, 2026

Study contacts

Hans Worthmann, PD Dr.
Contact
worthmann.hans@mh-hannover.de
+495115322393
Johannes Teller, Dr.
Contact
teller.johannes@mh-hannover.de
+495115323580

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion